11/02/2019 12:30:00

Theratechnologies Appoints General Manager in Europe

MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that its European subsidiary, Theratechnologies International Limited, has appointed Mr. Conor Walshe as its General Manager.

Mr. Walshe will be based in Dublin, Ireland, where Theratechnologies European head office will be established.

“We could not be happier with the hiring of Conor whom we will be able to rely on for his in-depth expertise, knowledge and acumen as we establish our presence in Europe. The potential launch of Trogarzo® in Europe requires the flawless implementation of an infrastructure that will be able to deliver on many key success factors including distribution, reimbursement, sales, marketing and relationships with key stakeholders,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

“Conor was selected as General Manager, after a thorough European search, based on his demonstrated capacity and ability to deliver on those critical issues for Theratechnologies in Europe.  As soon as he begins his mandate, he will be working with our contract sales organization on building the right field infrastructure in key European countries and he will complete the hiring of key internal strategic positions,” concluded Mr. Tanguay.

Prior to joining our European subsidiary, Mr. Walshe was General Manager and Vice President, Operations and Commercial, at Aralez Plc. Prior to Aralez Plc, Mr. Walshe spent more than 15 years in the pharmaceutical industry including at Perrigo Plc, Elan Plc and Venn Life Sciences where he was called upon to serve, among others, as CFO, Senior Vice President Commercial and Financial Operations and in product management.

Mr. Walshe is a Chartered Accountant. He holds a Bachelor of Commerce and a Master in Business Studies from the University College in Dublin. He also obtained a diploma in IFRS from the Institute of Chartered Accountants and in Advanced International Corporate Finance from INSEAD.  

About Theratechnologies

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them.  The forward-looking statements contained in this press release include, but are not limited to, statements about the potential launch of Trogarzo® in Europe and the building of an infrastructure in relation to the potential commercialization of Trogarzo® in Europe.

Forward-looking statements are subject to a number of assumptions and are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release.  These assumptions include, but are not limited to, the following: Trogarzo® will be approved for commercialization in Europe, our infrastructure will allow us to successfully commercialize Trogarzo® in Europe, and Trogarzo® will be reimbursed by each country in which it will be commercially sold.

The risks and uncertainties referred to above include, but are not limited to, the following: Trogarzo® may not be approved for commercialization in Europe, and even if approved, its indication may contain limitation restricting its use, healthcare professionals and patients may not accept Trogarzo® and reimbursement coverage, if any, for Trogarzo® may differ from one country to the other.

We refer potential investors to the "Risk Factors" section of our annual information form dated February 6, 2018 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

For media inquiries:

Denis Boucher

Vice President, Communications and Corporate Affairs

514-336-7800

Nouveau Logo communiqué de presse.JPG

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
47
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
36
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
24
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
10
18 Apr
 
Hej CasHolm   da du har en alder af 12 år syntes jeg at det er vigtigt at du gøre op med dig selv om..
10
17 Apr
 
Hej 'outlook', dit opslag blev slettet fordi det ikke omhandlede markedet eller værdipapirer på noge..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sprint Corp. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 12:06:25
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB4 - 2019-04-21 13:06:25 - 2019-04-21 12:06:25 - 1000 - Website: OKAY